MusclePharm market cap is $3.3 m, and annual revenue was $79.67 m in FY 2019

MusclePharm Gross profit (FY, 2019)8.7 M

MusclePharm Gross profit margin (FY, 2019), %10.9%

MusclePharm Net income (FY, 2019)-18.9 M

MusclePharm EBIT (FY, 2019)-15.1 M

MusclePharm Cash, 31-Dec-20191.5 M

MusclePharm EV13.3 M

MusclePharm revenue was $79.67 m in FY, 2019

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2019 |
---|---|---|---|---|---|---|---|---|

## Revenue | 17.2m | 67.1m | 110.9m | 177.4m | 166.9m | 132.5m | 102.2m | 79.7m |

| (6%) | (21%) | ||||||

## Cost of goods sold | 14.8m | 52.7m | 77.7m | 121.4m | 109.9m | 88.0m | 71.7m | 71.0m |

## Gross profit | 2.4m | 14.3m | 33.2m | 56.0m | 56.9m | 44.5m | 30.4m | 8.7m |

| 14% | 21% | 30% | 32% | 34% | 34% | 30% | 11% |

## Sales and marketing expense | 8.4m | 15.5m | 28.1m | 27.0m | 10.7m | 9.4m | 2.5m | |

## R&D expense | 1.1m | 4.0m | 4.3m | 1.9m | 642.0k | 893.0k | ||

## General and administrative expense | 18.6m | 23.1m | 47.5m | 13.4m | 19.4m | 15.9m | 12.1m | 8.9m |

## Operating expense total | 18.6m | 23.1m | 47.5m | 75.4m | 106.9m | 53.1m | 37.6m | 23.8m |

## EBIT | (16.2m) | (8.7m) | (14.3m) | (19.4m) | (49.9m) | (8.7m) | (7.2m) | (15.1m) |

| (94%) | (13%) | (13%) | (11%) | (30%) | (7%) | (7%) | (19%) |

## Interest expense | 3.7m | 7.3m | 783.3k | 5.6m | ||||

## Interest income | 250.0k | 50.0k | 1.4m | |||||

## Pre tax profit | (17.6m) | (13.8m) | (51.8m) | (3.2m) | (10.8m) | (18.8m) | ||

## Income tax expense | 115.5k | 33.0k | 105.0k | 318.0k | (108.0k) | 86.0k | ||

## Net Income | (23.3m) | (19.0m) | (17.7m) | (13.8m) | (51.9m) | (3.5m) | (11.0m) | (18.9m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2019 |
---|---|---|---|---|---|---|---|---|

## Net Income | (23.3m) | (19.0m) | (17.7m) | (13.8m) | (51.9m) | (3.5m) | (11.0m) | (18.9m) |

## Depreciation and Amortization | 171.6k | 475.3k | 7.3m | 2.0m | 2.8m | 2.1m | 1.5m | 659.0k |

## Accounts Receivable | (2.3m) | (742.7k) | (10.7m) | (2.6m) | (5.6m) | 7.3m | (4.6m) | 1.4m |

## Inventories | (4.5m) | 5.9m | (480.0k) | 2.1m | 8.9m | |||

## Accounts Payable | 7.6m | 10.1m | 23.1m | 5.0m | 14.2m | (20.8m) | 2.0m | (70.0k) |

## Cash From Operating Activities | (5.8m) | (697.6k) | (10.0m) | (4.1m) | 5.5m | (15.1m) | (5.1m) | (6.5m) |

## Purchases of PP&E | (831.5k) | (924.2k) | (1.9m) | (4.1m) | (1.5m) | (508.0k) | (37.0k) | (13.0k) |

## Cash From Investing Activities | (831.5k) | (965.3k) | (3.5m) | (1.6m) | (3.0m) | 5.4m | (37.0k) | (13.0k) |

## Short-term Borrowings | (2.5m) | (14.5m) | (3.0m) | (535.0k) | ||||

## Long-term Borrowings | (75.3k) | (5.8m) | (4.4m) | (104.0k) | (1.2m) | (3.2m) | (139.0k) | (41.1m) |

## Dividends Paid | ||||||||

## Cash From Financing Activities | 7.2m | 1.0m | 18.9m | 1.4m | 3.7m | 7.5m | 6.4m | 5.7m |

## Net Change in Cash | 616.1k | (659.8k) | 5.4m | (4.4m) | 6.1m | (2.1m) | 1.3m | (785.0k) |

## Interest Paid | 28.8k | 501.2k | 411.4k | 158.0k | 527.0k | 1.6m | 2.4m | 1.4m |

## Income Taxes Paid | 87.4k | 301.0k | 77.0k | 218.0k | 106.0k | 77.0k |

USD | Q2, 2011 |
---|---|

## Debt/Equity | -0.4 x |

## Debt/Assets | 0.4 x |

## Financial Leverage | -0.9 x |